Drug Overview
Novartis, under license from Vectura and Sosei, developed Utibron, a once-daily long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination product containing indacaterol and glycopyrrolate. The company has developed the components as monotherapies, and Arcapta (indacaterol) was the first product of the franchise to gain approval. Utibron received EU and Japanese approvals for use in COPD in September 2013, and launched in Germany and Japan in November 2013, ahead of GlaxoSmithKline’s Anoro ([umeclidinium + vilanterol]). The LABA/LAMA combination received US approval in October 2015.
Novartis, under license from Vectura and Sosei, developed Utibron, a once-daily long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) combination product containing indacaterol and glycopyrrolate. The company has developed the components as monotherapies, and Arcapta (indacaterol) was the first product of the franchise to gain approval. Utibron received EU and Japanese approvals for use in COPD in September 2013, and launched in Germany and Japan in November 2013, ahead of GlaxoSmithKline’s Anoro ([umeclidinium + vilanterol]). The LABA/LAMA combination received US approval in October 2015.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
